Emergent BioSolutions (NYSE:EBS) Trading Up 11.9% – Should You Buy?

Shares of Emergent BioSolutions Inc. (NYSE:EBS) rose 11.9% during mid-day trading on Monday . The company traded as high as $9.26 and last traded at $9.25. Approximately 357,293 shares were traded during trading, a decline of 88% from the average daily volume of 3,102,595 shares. The stock had previously closed at $8.27.

Wall Street Analyst Weigh In

A number of analysts have recently commented on EBS shares. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday. Benchmark boosted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. HC Wainwright initiated coverage on shares of Emergent BioSolutions in a research note on Monday. They set a “buy” rating and a $15.00 price target for the company. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Up 10.2 %

The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a fifty day simple moving average of $9.21 and a 200-day simple moving average of $8.89. The firm has a market cap of $493.62 million, a price-to-earnings ratio of -2.22 and a beta of 1.59.

Hedge Funds Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently made changes to their positions in the company. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions during the 2nd quarter worth $41,000. Verus Capital Partners LLC acquired a new stake in shares of Emergent BioSolutions during the 2nd quarter worth $68,000. Vanguard Personalized Indexing Management LLC bought a new stake in Emergent BioSolutions during the second quarter worth about $93,000. Stifel Financial Corp acquired a new stake in Emergent BioSolutions during the third quarter worth about $96,000. Finally, Morse Asset Management Inc bought a new position in Emergent BioSolutions in the 2nd quarter valued at about $97,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.